MD4844B1 - Utilizare a derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi - Google Patents

Utilizare a derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi Download PDF

Info

Publication number
MD4844B1
MD4844B1 MDA20210050A MD20210050A MD4844B1 MD 4844 B1 MD4844 B1 MD 4844B1 MD A20210050 A MDA20210050 A MD A20210050A MD 20210050 A MD20210050 A MD 20210050A MD 4844 B1 MD4844 B1 MD 4844B1
Authority
MD
Moldova
Prior art keywords
steroid resistance
glutarimide derivative
overcome
overcome steroid
resistance
Prior art date
Application number
MDA20210050A
Other languages
English (en)
Russian (ru)
Other versions
MD20210050A2 (ro
MD4844C1 (ro
Inventor
Владимир НЕБОЛЬСИН
Original Assignee
Общество С Ограниченной Ответственностью "Фарминтерпрайсез"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Фарминтерпрайсез" filed Critical Общество С Ограниченной Ответственностью "Фарминтерпрайсез"
Publication of MD20210050A2 publication Critical patent/MD20210050A2/ro
Publication of MD4844B1 publication Critical patent/MD4844B1/ro
Publication of MD4844C1 publication Critical patent/MD4844C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Invenţia se referă la medicină, în particular la un medicament, eficient pentru depăşirea rezistenţei la steroizi şi tratamentul tulburărilor la pacienţii cu rezistenţă la steroizi, cum ar fi astmul bronşic, prin utilizarea compusului 1-(2-(1H-imidazol-4-il)etil)piperidin-2,6-dionă:.
MDA20210050A 2018-11-23 2019-11-22 Utilizare a derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi MD4844C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2018141291A RU2712281C1 (ru) 2018-11-23 2018-11-23 Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
PCT/RU2019/050225 WO2020106191A1 (ru) 2018-11-23 2019-11-22 Производное глутаримида для преодоления резистентности к стероидам

Publications (3)

Publication Number Publication Date
MD20210050A2 MD20210050A2 (ro) 2021-12-31
MD4844B1 true MD4844B1 (ro) 2023-02-28
MD4844C1 MD4844C1 (ro) 2023-09-30

Family

ID=69624712

Family Applications (2)

Application Number Title Priority Date Filing Date
MDA20210050A MD4844C1 (ro) 2018-11-23 2019-11-22 Utilizare a derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi
MDA20210032A MD4851C1 (ro) 2018-11-23 2019-11-22 Utilizarea derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi

Family Applications After (1)

Application Number Title Priority Date Filing Date
MDA20210032A MD4851C1 (ro) 2018-11-23 2019-11-22 Utilizarea derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi

Country Status (19)

Country Link
US (1) US20220362230A1 (ro)
EP (2) EP4218758A3 (ro)
JP (2) JP2022508167A (ro)
KR (2) KR20210095652A (ro)
CN (2) CN113164464A (ro)
AU (2) AU2019384626A1 (ro)
BR (1) BR112021009801A2 (ro)
CA (1) CA3120882A1 (ro)
CL (2) CL2021001316A1 (ro)
EA (1) EA201992646A1 (ro)
GE (4) GEAP202215712A (ro)
IL (2) IL297533A (ro)
MD (2) MD4844C1 (ro)
MX (2) MX2021006032A (ro)
MY (1) MY209416A (ro)
PH (1) PH12021551152A1 (ro)
RU (1) RU2712281C1 (ro)
WO (1) WO2020106191A1 (ro)
ZA (2) ZA202104247B (ro)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023177329A1 (ru) * 2022-03-18 2023-09-21 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями
CN118922413A (zh) * 2022-03-29 2024-11-08 瓦伦塔有限责任公司 1-(2-(1н-咪唑-4-基)乙基)哌啶-2,6-二酮的晶型及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9111874U1 (de) * 1991-09-23 1991-11-21 Haag, Richard, 7181 Satteldorf Halterung zur Aufnahme und Befestigung von Akkus am Heckbrett in Booten
JP2927961B2 (ja) * 1992-02-07 1999-07-28 エム． クリグマン，アルバート 炎症性皮膚病の治療方法
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
WO2009037584A2 (en) 2007-08-10 2009-03-26 Topigen Pharmaceuticals Inc. Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease
RU2404792C1 (ru) * 2009-05-20 2010-11-27 Общество с ограниченной ответственностью Научно-производственное предприятие "БИОНОКС" Средство для преодоления стероидной резистентности
AU2012214417A1 (en) * 2011-02-10 2013-09-05 Genqual Corporation Methods of prognosing and administering treatment for inflammatory disorders
JP2014511181A (ja) 2011-02-24 2014-05-15 ファーマキシス リミテッド キメラ骨格および２−アミノ−２’−デオキシアデノシンを有するオリゴヌクレオチド阻害剤
EP3725785B1 (en) * 2013-04-12 2024-04-10 Nebolsin, Vladimir Glutarimide derivative, use thereof, pharmaceutical composition based thereon and methods for producing the glutarimide derivative
RU2552929C1 (ru) * 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
GEP20227402B (en) * 2017-09-07 2022-08-10 Valenta Intellekt Ltd Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines

Also Published As

Publication number Publication date
CN113164464A (zh) 2021-07-23
BR112021009801A2 (pt) 2022-03-03
GEP20237467B (en) 2023-02-10
AU2019384626A1 (en) 2021-07-15
ZA202210444B (en) 2023-01-25
JP2022508167A (ja) 2022-01-19
CL2022000683A1 (es) 2022-10-28
MY209416A (en) 2025-07-08
MD20210032A2 (ro) 2021-09-30
JP2023015333A (ja) 2023-01-31
GEAP202215712A (en) 2022-10-10
GEP20247643B (en) 2024-07-10
MX2021006032A (es) 2021-07-06
MD4851B1 (ro) 2023-04-30
EP4218758A3 (en) 2023-08-23
IL283317A (en) 2021-07-29
AU2022256212A1 (en) 2022-12-08
ZA202104247B (en) 2023-03-29
AU2022256212B2 (en) 2024-08-15
MD20210050A2 (ro) 2021-12-31
IL297533A (en) 2022-12-01
CA3120882A1 (en) 2020-05-28
EA201992646A1 (ru) 2020-05-31
MD4844C1 (ro) 2023-09-30
MD4851C1 (ro) 2023-11-30
PH12021551152A1 (en) 2021-10-25
RU2712281C1 (ru) 2020-01-28
WO2020106191A1 (ru) 2020-05-28
EP3884945A4 (en) 2022-11-23
EP4218758A2 (en) 2023-08-02
US20220362230A1 (en) 2022-11-17
CL2021001316A1 (es) 2021-10-29
EP3884945A1 (en) 2021-09-29
KR20210095652A (ko) 2021-08-02
JP7518997B2 (ja) 2024-07-19
GEAP202415619A (en) 2024-03-11
KR20220162821A (ko) 2022-12-08
MX2022013503A (es) 2022-11-16
CN114652721A (zh) 2022-06-24

Similar Documents

Publication Publication Date Title
CY1125436T1 (el) Αναστολεις dna-pk
MX2024004332A (es) Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos.
EA201890001A1 (ru) Замещенные гетероциклические производные как ингибиторы циклинзависимой киназы (cdk)
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
BR112017007662A2 (pt) composto, composição farmacêutica, processo de elaboração de uma composição farmacêutica, método de tratamento de distúrbio ou doença relativa a er, kit de tratamento e uso de composto
CY1125488T1 (el) Παραγωγα πυριδινης και θεραπευτικες χρησεις αυτων ως αναστολεις trpc6
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
MX386089B (es) Compuesto heterociclico utilizado como inhibidor de fgfr.
EA201490300A1 (ru) 4-имидазопиридазин-1-ил-бензамиды и 4-имидазотриазин-1-ил-бензамиды в качестве btk-ингибиторов
MX386782B (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
EA201500362A1 (ru) Ингибиторы rho-киназы
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
EA201691404A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов бромодомена
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
SA520411783B1 (ar) مشتقات إيميدازول مكثفة بها استبدال بمجموعات هيدروكسي ثلاثية كمثبطات جاما لـ pi3k-
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX390082B (es) Derivados de adenina como inhibidores de proteína quinasa
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
CY1118818T1 (el) Παραγωγα 1-[1-(benzoϋλ)-πυρρολιδινο-2-καρβονυλο]-πυρρολιδινο-2-καρβονιτριλιου
ATE439831T1 (de) Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung

Legal Events

Date Code Title Description
FG4A Patent for invention issued